Sign In
Buy VTRS
$16.39
+0.120 (+0.738%)
At Close: Jul 13, 2026
Could This New Drug Launch Be a Hit for Viatris?
08:00am, Thursday, 12'th Jan 2023
Viatris and Kindeva Drug Delivery could soon launch a generic version of AstraZeneca's Symbicort.
Viatris Inc. (VTRS) 41st Annual J.P. Morgan Healthcare Conference (Transcript)
11:30pm, Wednesday, 11'th Jan 2023
Viatris Inc. (NASDAQ:VTRS ) 41st Annual J.P. Morgan Healthcare Conference January 11, 2023 6:00 PM ET Company Participants Michael Goettler - CEO Rajiv Malik - President Jeffrey Nau - Head, Eye Care C
Is Now the Time to Buy 3 of the S&P 500's Cheapest Stocks?
05:05am, Wednesday, 04'th Jan 2023
All of these stocks are trading at less than 7 times their future profits.
Why These 7 Healthcare Stocks Could Soar in 2023
07:22am, Monday, 02'nd Jan 2023
With the healthcare sector poised to grow significantly in the coming years, healthcare stocks to buy present a fantastic opportunity for investors. Healthcare is something that everyone will need at
1 Passive Income Stock to Buy While It's Cheap and 1 to Avoid
09:15am, Thursday, 29'th Dec 2022
Both businesses are well-suited for producing passive income, but only one has the balance sheet and future prospects to make it work.
The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond
09:04am, Sunday, 18'th Dec 2022
Major indices such as the S&P 500 and the Nasdaq Composite may have plunged by double-digits during 2022, but certain areas of the stock market performed strongly throughout the year. One of those
Want $3,000 in Dividend Income Next Year? Invest $50,000 in These 2 Stocks
05:10am, Wednesday, 07'th Dec 2022
These stocks have dividend yields exceeding 4%.
Better Dividend Stock: AbbVie or Viatris?
08:15am, Saturday, 26'th Nov 2022
These pharmaceutical companies are profitable and offer above-average dividends.
3 Stocks With Dividends of 3% or More to Buy on the Dip
09:30am, Monday, 14'th Nov 2022
Three underpriced healthcare stocks provide an opportunity.
Viatris (VTRS) Wins in Court Against AstraZeneca's Symbicort
12:02pm, Friday, 11'th Nov 2022
Viatris (VTRS) and its partner win a court decision that invalidates branded drug Symbicort's patent and opens the door for them to launch their generic version of the drug.
Viatris Executive Charged With Insider Trading
06:54pm, Thursday, 10'th Nov 2022
Prosecutors and regulators say Ramkumar Rayapureddy, global chief information officer, tipped a friend about a regulatory drug approval.
Want to Collect a High Dividend Every Month? Buy These 3 Stocks
05:10am, Thursday, 10'th Nov 2022
Together, these stocks will ensure you're receiving a dividend each month of the year.
Making Sense of the Earnings Picture and Estimate Revisions
07:34pm, Wednesday, 09'th Nov 2022
Looking at 2022 Q3 as a whole, total S&P 500 earnings are currently expected to be up +1.5% from the same period last year on +11.4% higher revenues. Excluding contributions from the Energy sector, Q3
Making Sense of the Earnings Picture and Estimate Revisions
07:34pm, Wednesday, 09'th Nov 2022
Looking at 2022 Q3 as a whole, total S&P 500 earnings are currently expected to be up +1.5% from the same period last year on +11.4% higher revenues. Excluding contributions from the Energy sector, Q3
Viatris: A Spinoff That Got Even More Interesting
11:28am, Wednesday, 09'th Nov 2022
Viatris' business is holding up better than expected, despite FX headwinds. A new path to growth clears visibility for investors as the company targets to be the next ophthalmology leader.
